Evidence map›Paper›PMID 17343740›Full record

ArticleMolecular cancer2007

Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.

Bhavik Desai, Michael J Rogers, Meenakshi A Chellaiah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 156 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Bhavik DesaiDepartment of Biomedical Sciences, Dental School, University of Maryland, Baltimore, MD 21201, USA. bdesa002@umaryland.edu
Michael J Rogers
Meenakshi A Chellaiah
University of Maryland, Baltimore · USUniversity of Aberdeen · GB

Funding

Regulation of Signaling in Osteoclast Bone ResorptionR01AR046292 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI CHELLAIAH, MEENAKSHI A · 1999 to 2007
$1.8M
NIAMS NIH HHS R01 AR046292NIAMS NIH HHS R01-AR46292
6 · The paper itself

Abstract

backgroundThe expression level of osteopontin correlates with the metastatic potential of several tumors. Osteopontin is a well-characterized ligand for the alphavbeta3 integrin. The present study was undertaken to elucidate the possible role of osteopontin/alphavbeta3 signaling in prostate cancer cell migration.

resultsWe generated stable prostate cancer cell (PC3) lines that over-express osteopontin (PC3/OPN), mutant OPN in the integrin binding-site (PC3/RGDDeltaRGA), and null for OPN (PC3/SiRNA). The following observations were made in PC3/OPN cells as compared with PC3 cells: 1) an increase in multinucleated giant cells and RANKL expression; 2) an increase in CD44 surface expression, interaction of CD44/MMP-9 on the cell surface, MMP-9 activity in the conditioned medium, and cell migration; 3) western blot analysis of concentrated conditioned medium exhibited equal levels of MMP-9 protein in all PC3 cells. However, zymography analysis demonstrated that the levels of MMP-9 activity in the conditioned media reflect the CD44 surface expression pattern of the PC3 cell lines; 4) although MMP-9 and MMP-2 are secreted by PC3 cells, only the secretion of MMP-9 is regulated by OPN expression. A strong down regulation of the above-mentioned processes was observed in PC3/OPN (RGA) and PC3/SiRNA cells. PC3/OPN cells treated with bisphosphonate (BP) reproduce the down-regulation observed in PC3/OPN (RGA) and PC3/SiRNA cells.

conclusionRho signaling plays a crucial role in CD44 surface expression. BPs inhibits the mevalonate pathway, which in turn, prevents the prenylation of a number of small GTPases. Attenuation of Rho GTPase activation by BPs may have contributed to the down regulation of cell surface CD44/MMP-9 interaction, MMP-9 activation/secretion, and cell migration. Taken together, these observations suggest that CD44 surface expression is an important event in the activation of MMP-9 and migration of prostate cancer cells. The various steps involved in the above mentioned signaling pathway and/or the molecules regulating the activation of MMP-9 are potential therapeutic target.

Indexed as

AdenocarcinomaBone NeoplasmsCell AdhesionCell Line, TumorCell MovementDiphosphonatesEnzyme ActivationGiant CellsHumansHyaluronan ReceptorsIntegrin alphaVbeta3MaleMatrix Metalloproteinase 9Mevalonic AcidMutant ProteinsNeoplasm InvasivenessCD44 protein, humanDiphosphonatesHyaluronan ReceptorsIntegrin alphaVbeta3Matrix Metalloproteinase 9Mevalonic AcidMutant ProteinsNeoplasm ProteinsOsteopontinRANK LigandRecombinant Fusion Proteinsrho GTP-Binding ProteinsRNA, Small InterferingTNFSF11 protein, human

Identifiers

PMID17343740
PMCPMC1828067
OpenAlexW2143904769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.